Table 4.
Interaction between treatment regimen status and other significant prognostic factors and its effect on disease-free survival, distant metastasis-free survival, loco-regional relapse-free survival, and overall survival
| Disease-free survival | Loco-regional relapse-free survival | Distant metastasis-free survival | Overall survival | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Adjusted HRa (95% CI) | P value | Adjusted HRa (95% CI) |
P value | Adjusted HRa (95% CI) | P value | Adjusted HRa (95% CI) | P value | ||||
| Treatment regimen status and Node Stage | |||||||||||
| Treatment regimen status | |||||||||||
| CCRT alone | Reference | Reference | Reference | Reference | |||||||
| CTX/NTZ plus CCRT | 0.43 (0.19-0.98) |
0.042 | 0.50 (0.16-1.61) |
0.247 | 0.40 (0.15-1.09) |
0.074 | 0.42 (0.13-1.32) |
0.137 | |||
| Node Stage | |||||||||||
| N0-N1 | Reference | Reference | Reference | Reference | |||||||
| N2 | 1.53 (1.12-2.10) |
0.008 | 1.36 (0.82-2.27) |
0.230 | 1.53 (1.06-2.20) |
0.023 | 1.87 (1.26-2.77) |
0.002 | |||
| N3 | 4.08 (1.71-9.72) |
0.002 | 4.84 (1.15-20.34) |
0.032 | 2.92 (1.05-8.14) |
0.041 | 5.46 (1.98-15.02) |
0.001 | |||
| Interaction Effect | |||||||||||
| CTX/NTZ plus CCRT * N2 | 1.66 (0.58-4.76) |
0.346 | 1.04 (0.20-5.48) |
0.967 | 1.69 (0.47-6.05) |
0.420 | 0.93 (0.20-4.37) |
0.929 | |||
| CTX/NTZ plus CCRT * N3 | 1.46 (0.27-7.90) |
0.662 | 2.30 (0.20-26.98) |
0.509 | 1.75 (0.29-10.42) |
0.540 | 1.05 (0.10-11.07) |
0.970 | |||
| Treatment regimen status and Tumor Stage | |||||||||||
| Treatment regimen status | |||||||||||
| CCRT alone | Reference | Reference | Reference | Reference | |||||||
| CTX/NTZ plus CCRT | 0.90 (0.19-4.34) |
0.893 | 0.30 (0.03-3.06) |
0.307 | 1.08 (0.16-7.12) |
0.936 | 0.46 (0.05-4.08) |
0.484 | |||
| Tumor Stage | |||||||||||
| T1-T3 | Reference | Reference | Reference | Reference | |||||||
| T4 | 2.79 (1.10-7.08) |
0.030 | 4.55 (0.92-22.48) |
0.063 | 1.58 (0.55-4.54) |
0.397 | 3.30 (1.11-9.84) |
0.032 | |||
| Interaction Effect | |||||||||||
| CTX/NTZ plus CCRT * T4 | 0.69 (0.19-2.47) |
0.563 | 1.65 (0.29-9.29) |
0.569 | 0.57 (0.12-2.70) |
0.480 | 0.90 (0.17-4.70) |
0.902 | |||
The data originate from all 1628 patients included in the study: HR, Hazard ratio; CI, confidence interval. a Multivariable cox regression model adjusted for age, gender, Karnofsky performance status score, tumor stage, node stage, disease stage